Pretreatment HDL‐C and ApoA1 are predictive biomarkers of progression‐free survival in patients with EGFR mutated advanced non‐small cell lung cancer treated with TKI

Abstract Background We aimed to explore the correlation between blood lipids (high density lipoprotein cholesterol [HDL‐C] and apolipoprotein A1 [ApoA1]) and epidermal growth factor receptor (EGFR) T790M mutation, as well as its predictive role in clinical efficacy and progression‐free survial (PFS)...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Juan Ma, Ying Bai, Mei Liu, Tong Jiao, Yang Chen, Bo Yuan, Boxuan Liu, Lizhong Zeng, Zongjuan Ming, Wei Li, Ruiying Sun, Xia Yang, Shuanying Yang
Médium: Artigo
Jazyk:Inglês
Vydáno: Wiley 2022-04-01
Edice:Thoracic Cancer
Témata:
advanced non‐small cell lung cancer
apolipoprotein A1
epidermal growth factor receptor
high density lipoprotein cholesterol
progression‐free survival
On-line přístup:https://doi.org/10.1111/1759-7714.14367
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky